Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML

FXa variants advance toward a therapy for bleeding

(2015) J. Emsley   BLOOD

FLT3-ITD confers resistance to the PI3K/Akt pathway inhibitors by protecting the mTOR/4EBP1/Mcl-1 pathway through STAT5 activation in acute myeloid leukemia

(2015) Ayako Nogami et al.   Oncotarget

A novel tescalcin-sodium/hydrogen exchange axis underlying sorafenib resistance in FLT3-ITD+ AML

(2014) C. H. Man et al.   BLOOD

The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models

(2014) V D'Amato et al.   BRITISH JOURNAL OF CANCER

SYK Is a Critical Regulator of FLT3 in Acute Myeloid Leukemia

(2014) Alexandre Puissant et al.   CANCER CELL

Dual PI3K/mTOR inhibition shows antileukemic activity in MLL-rearranged acute myeloid leukemia

(2014) N Sandhöfer et al.   LEUKEMIA

Deciphering Combinations of PI3K/AKT/mTOR Pathway Drugs Augmenting Anti-Angiogenic Efficacy In Vivo

(2014) Temitope Sasore et al.   PLoS One

A Diverse Array of Cancer-Associated MTOR Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity

(2014) B. C. Grabiner et al.   Cancer Discovery

Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD

(2013) C. C. Smith et al.   BLOOD

The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib

(2013) C Albers et al.   LEUKEMIA

FLT3tyrosine kinase inhibitors in acute myeloid leukemia: clinical implications and limitations

(2013) Sabine Kayser et al.   LEUKEMIA & LYMPHOMA

An Adaptive Alignment Algorithm for Quality-controlled Label-free LC-MS

(2013) Marianne Sandin et al.   MOLECULAR & CELLULAR PROTEOMICS

mTOR kinase structure, mechanism and regulation

(2013) Haijuan Yang et al.   NATURE

Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia

(2013)   NEW ENGLAND JOURNAL OF MEDICINE

The PI3-kinase isoform p110δ is essential for cell transformation induced by the D816V mutant of c-Kit in a lipid-kinase-independent manner

(2013) J Sun et al.   ONCOGENE

Sorafenib treatment of FLT3-ITD+ acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation

(2012) C. H. Man et al.   BLOOD

FLT3 inhibition: a moving and evolving target in acute myeloid leukaemia

(2012) A Y H Leung et al.   LEUKEMIA

Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia

(2012) Catherine C. Smith et al.   NATURE

Stem Cell Factor Receptor/c-Kit: From Basic Science to Clinical Implications

(2012) Johan Lennartsson et al.   PHYSIOLOGICAL REVIEWS

Antitumor Efficacy of PKI-587, a Highly Potent Dual PI3K/mTOR Kinase Inhibitor

(2011) R. Mallon et al.   CLINICAL CANCER RESEARCH

PKI-587 and Sorafenib Targeting PI3K/AKT/mTOR and Ras/Raf/MAPK Pathways Synergistically Inhibit HCC Cell Proliferation

(2011) Roberto Gedaly et al.   JOURNAL OF SURGICAL RESEARCH

Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway

(2011) A M Martelli et al.   LEUKEMIA

Mechanisms of resistance against PKC412 in resistant FLT3-ITD positive human acute myeloid leukemia cells

(2010) Friedrich Stölzel et al.   ANNALS OF HEMATOLOGY

AML1 is overexpressed in patients with myeloproliferative neoplasms and mediates JAK2V617F-independent overexpression of NF-E2

(2010) W. Wang et al.   BLOOD

Bis(morpholino-1,3,5-triazine) Derivatives: Potent Adenosine 5′-Triphosphate Competitive Phosphatidylinositol-3-kinase/Mammalian Target of Rapamycin Inhibitors: Discovery of Compound26(PKI-587), a Highly Efficacious Dual Inhibitor

(2010) Aranapakam M. Venkatesan et al.   JOURNAL OF MEDICINAL CHEMISTRY

A novel molecular mechanism of primary resistance to FLT3-kinase inhibitors in AML

(2009) F. Breitenbuecher et al.   BLOOD

Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome

(2009) B. J. Wouters et al.   BLOOD

FMS-Like Tyrosine Kinase 3-Internal Tandem Duplication Tyrosine Kinase Inhibitors Display a Nonoverlapping Profile of Resistance Mutations In vitro

(2009) N. von Bubnoff et al.   CANCER RESEARCH

Biochemical, Cellular, and In vivo Activity of Novel ATP-Competitive and Selective Inhibitors of the Mammalian Target of Rapamycin

(2009) K. Yu et al.   CANCER RESEARCH

Oncogenic signaling from the hematopoietic growth factor receptors c-Kit and Flt3

(2009) Kristina Masson et al.   CELLULAR SIGNALLING

Oncogenic Flt3 receptors display different specificity and kinetics of autophosphorylation

(2009) Elena Razumovskaya et al.   EXPERIMENTAL HEMATOLOGY

Characterization of the expression of HTm4 (MS4A3), a cell cycle regulator, in human peripheral blood cells and normal and malignant tissues

(2009) Jeffery L. Kutok et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

The Proteios Software Environment: An Extensible Multiuser Platform for Management and Analysis of Proteomics Data

(2009) Jari Häkkinen et al.   JOURNAL OF PROTEOME RESEARCH

Structural and numerical variation of FLT3/ITD in pediatric AML

(2008) S. Meshinchi et al.   BLOOD

Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry

(2008) G. Juliusson et al.   BLOOD